SS-31 Study Explained: SS-31 improves post-cardiac arrest brain injury by inhibiting microglial

Quick answer

In a mouse model of ischemic stroke, a combination of elamipretide and nicotinamide mononucleotide (NMN) significantly reduced post-ischemic brain damage and improved neurological deficits compared to either compound alone.¹

This is an animal study, and the result is for the combination, not elamipretide alone.¹ For Filipino readers, the useful next step is to keep that finding tied to the cited study and verify any local product claim separately. That keeps the answer specific and easy to check.

What did researchers actually examine?

For readers following SS-31 study on improves post-cardiac arrest brain, the order matters: identify the study setting, read the result, then place the limitation beside it.

The source describes a focused result: in a mouse model of ischemic stroke, a combination of elamipretide and nicotinamide mononucleotide (NMN) significantly reduced post-ischemic brain damage and improved neurological deficits compared to either compound alone.¹

The population and method are part of the answer: the study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy.¹

The source also narrows the conclusion: this is an animal study, and the result is for the combination, not elamipretide alone.¹

Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.

What was the clearest result?

A result becomes easier to trust when the SS-31 study on improves post-cardiac arrest brain details stay visible. Population, method, outcome, and timeframe all belong near the conclusion.

The paper’s main result was that a post hoc analysis of the MMPOWER-3 trial found that a subgroup of participants with nuclear DNA defects affecting the mtDNA replisome showed a trend toward improvement on the six-minute walk test.²

The study context keeps the conclusion precise: the post hoc analysis reported that the mtDNA replisome cohort displayed an improvement on the 6MWT, trending towards significant, in the elamipretide group compared with placebo (25.2 m versus 2.0 m; p = 0.06).²

That result does not erase its main limit: this is a post hoc analysis of a trial that did not meet its primary endpoints, and the finding was not statistically significant.²

What does the wider research add?

The practical reading of SS-31 study on improves post-cardiac arrest brain is specific rather than dramatic. Keep the measured outcome, the comparison, and the study setting attached to one another.

The central finding was specific: in a mouse model of ischemic stroke, a combination of elamipretide and nicotinamide mononucleotide (NMN) significantly reduced post-ischemic brain damage and improved neurological deficits compared to either compound alone.¹

That result came from this context: the study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy.¹

The finding should stop here: this is an animal study, and the result is for the combination, not elamipretide alone.¹

Which limits belong beside the finding?

The useful question in this SS-31 study on improves post-cardiac arrest brain story is not whether the headline sounds impressive. It is whether the population, outcome, and comparison still match the cited source.

The source describes a focused result: a post hoc analysis of the MMPOWER-3 trial found that a subgroup of participants with nuclear DNA defects affecting the mtDNA replisome showed a trend toward improvement on the six-minute walk test.²

The population and method are part of the answer: the post hoc analysis reported that the mtDNA replisome cohort displayed an improvement on the 6MWT, trending towards significant, in the elamipretide group compared with placebo (25.2 m versus 2.0 m; p = 0.06).²

The source also narrows the conclusion: this is a post hoc analysis of a trial that did not meet its primary endpoints, and the finding was not statistically significant.²

How does product identity fit the story?

For readers following SS-31 study on improves post-cardiac arrest brain, the order matters: identify the study setting, read the result, then place the limitation beside it.

The paper’s main result was that SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.³

The study context keeps the conclusion precise: the FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding.³

That result does not erase its main limit: this is a description of its mechanism of action from regulatory and laboratory sources.³

The study reported that in a long-term open-label extension of the TAZPOWER trial, people with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the six-minute walk test over 168 weeks.⁴ The main limit is equally important: this was an open-label study with a small number of participants, and all knew they were receiving the active drug.⁴

The central finding was specific: WHO states that some falsified medical products can closely resemble genuine products and may require quality-control analysis.⁵ The finding should stop here: appearance alone cannot authenticate a product or establish a research outcome.⁵

Readers comparing this topic with MOTS-C can view its live catalog details below. It is a separate catalog reference, not a suggested combination.

What should Filipino readers verify?

A result becomes easier to trust when the SS-31 study on improves post-cardiac arrest brain details stay visible. Population, method, outcome, and timeframe all belong near the conclusion.

The central finding was specific: in a 12-week randomized trial of 12 males with Barth syndrome, the primary endpoints included the distance walked in six minutes and a measure of muscle strength.⁶

That result came from this context: the FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome.⁶

The finding should stop here: the snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints.⁶

Researchers found that the Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁷ One caution belongs beside that result: a portal record applies to the exact product or establishment named in that record.⁷

Bottom line

The clearest reading is that in a mouse model of ischemic stroke, a combination of elamipretide and nicotinamide mononucleotide (NMN) significantly reduced post-ischemic brain damage and improved neurological deficits compared to either compound alone.¹

This is a description of its mechanism of action from regulatory and laboratory sources.³ For Filipino readers, the research result and the exact local product record remain separate checks.

That approach keeps SS-31 informative without turning one study into personal advice, a universal promise, or proof about a catalog product.

Frequently asked questions

What is the short answer about SS-31?

The cited source gives a focused answer: in a mouse model of ischemic stroke, a combination of elamipretide and nicotinamide mononucleotide (NMN) significantly reduced post-ischemic brain damage and improved neurological deficits compared to either compound alone.¹ The conclusion stays tied to that study’s population, method, and measured outcome.

Does one positive result settle the whole topic?

No. This is a post hoc analysis of a trial that did not meet its primary endpoints, and the finding was not statistically significant.² A useful result can remain narrow without being dismissed or promoted as a universal benefit.

Why does the study context matter?

The FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding.³ Changing the population, comparison, formulation, or endpoint would change the question, so those details belong beside the finding.

What should Filipino readers verify?

SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.³ Check the exact name and record shown by the official source instead of assuming that a familiar molecule name covers every listing.

Do the SS-31 and MOTS-C cards prove a benefit?

No. In this SS-31 study on improves post-cardiac arrest brain guide, the cards are live catalog references for navigation. They do not prove study equivalence, turn research into a product claim, or suggest that the two items should be used together.⁸

Sources

Footnotes

1. Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.. The study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy. This is an animal study, and the result is for the combination, not elamipretide alone. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰

2. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.. The post hoc analysis reported that the mtDNA replisome cohort displayed an improvement on the 6MWT, trending towards significant, in the elamipretide group compared with placebo (25.2 m versus 2.0 m; p = 0.06). This is a post hoc analysis of a trial that did not meet its primary endpoints, and the finding was not statistically significant. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

3. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.. The FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding. This is a description of its mechanism of action from regulatory and laboratory sources. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

4. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. The 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it. This was an open-label study with a small number of participants, and all knew they were receiving the active drug. ↩ ↩²

5. WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩ ↩²

6. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE). The FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome. The snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints. ↩ ↩² ↩³

7. Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩²

8. Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.; Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.; FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩